Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy
Oxford Medical Case Reports · 08.06.2026 · 2026 (6)
DOI: 10.1093/omcr/omag079 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oxford Medical Case Reports, online erschienen am 15.06.2026. Verfasst von Carolina Barbosa Carvalho do Carmo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rosai–Dorfman disease (RDD) is a rare histiocytic disorder, usually benign but may follow an aggressive and treatment-refractory course in a subset of patients. Somatic mutations involving the MAPK/ERK pathway, particularly KRAS and MAP2K1, have been increasingly recognized and provide a rationale for targeted therapy. We report the case of a 41-year-old woman with a two-year history of progressive, multisystem RDD presenting with cervical and mediastinal lymphadenopathy and laryngeal involvement, who was refractory to multiple conventional treatments, including corticosteroids, immunosuppressive agents, immunomodulatory drugs, and chemotherapy. Next-generation sequencing identified a pathogenic MAP2K1 c.607G > A mutation, leading to initiation of MEK inhibition with cobimetinib. The patient achieved complete clinical and radiological response, which has been sustained for more than three years after treatment discontinuation. This case highlights the importance of molecular profiling in refractory RDD and supports MEK inhibition as a promising therapeutic strategy in patients with actionable MAPK pathway mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil.
- Laboratório Diagnose, SGAS 915, Conjunto F, Asa Sul, DF, 70390-150 Brasília, Brazil.
- Oncolínicas DF, SGAS 915, Conjunto F, Asa Sul, DF, 70390-150 Brasília, Brazil.
ORCID-Profile: Carolina Barbosa Carvalho do Carmo, Ana Luiza Potiguara de Sousa
Zitieren
APA
Barbosa Carvalho do Carmo, C., Potiguara de Sousa, A. L., de Souza Alves Glória, G. H., Serpa Andrade Borges, I., Cervantes Sartorelli, A., & Nonino, A. (2026). Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy. Oxford Medical Case Reports, 2026(6). https://doi.org/10.1093/omcr/omag079
Vancouver
Barbosa Carvalho do Carmo C, Potiguara de Sousa AL, de Souza Alves Glória GH, Serpa Andrade Borges I, Cervantes Sartorelli A, Nonino A. Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy. Oxford Medical Case Reports. 2026;2026(6). doi:10.1093/omcr/omag079
BibTeX
@article{BarbosaCarvalhodoCarmo2026,
author = {Barbosa Carvalho do Carmo, Carolina and Potiguara de Sousa, Ana Luiza and de Souza Alves Glória, Gabriel Henrique and Serpa Andrade Borges, Isabella and Cervantes Sartorelli, Alesso and Nonino, Alexandre},
title = {Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy},
journal = {Oxford Medical Case Reports},
year = {2026},
volume = {2026},
number = {6},
doi = {10.1093/omcr/omag079}
}
EUVIMED